CQCristiano Quintini

Cristiano Quintini

*This is an algorithmically generated author record based on publicly available information.

Cristiano Quintini has a total of 248 co-authors. Here are the top co-authors by number of shared publications:

  • Teresa Diago Uso

    Transplantation Center, Department of Surgery, Digestive Disease Institute, Cleveland Clinic, OH

    21 shared publications
  • Charles Miller

    Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, USA

    19 shared publications
  • Koji Hashimoto

    Department of Inflammation & Immunity, Lerner Research Institute, Cleveland Clinic, Cleveland, USA

    18 shared publications
  • Qiang Liu

    Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, USA

    15 shared publications
  • Bijan Eghtesad

    Transplantation Center, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, Ohio

    12 shared publications
  • Federico Aucejo

    Transplantation Center, Department of Surgery, Digestive Disease Institute, Cleveland Clinic, OH

    11 shared publications

Latest Publications

  • Quasi Ischemia‐Free Liver Procurement: A Novel Technique to Decrease Graft Injury With Normothermic Machine Perfusion

    by Cristiano Quintini, Teresa Diago Uso, Koji Hashimoto, Beatrice Cazzaniga, Qiang Liu, Luca Del Prete

    Background: Normothermic machine perfusion has emerged as a valuable technique for organ preservation, enabling liver viability assessment and reducing the discard rates of marginal grafts. However, the standard protocol involves two cooling/rewarming phases, which can result in a double ischemia/reperfusion injury that increases the risk of graft dysfunction. Methods: We describe a novel surgical technique, named quasi ischemia‐free liver procurement, which circumvents cold ischemia during liver procurement, thereby minimizing ischemia–reperfusion injury. Results: In this study, we applied quasi‐ischemia‐free liver procurement to an orphan liver graft from a 43‐year‐old deceased brain donor. The liver was subsequently transplanted into a 66‐year‐old male recipient with alcoholic liver cirrhosis and hepatocellular carcinoma. The technique was successful, with ex‐situ normothermic perfusion beginning within 3 min of graft disconnection without graft cooling and lasting for nearly 4 h. The graft exhibited excellent viability, evidenced by immediate lactate clearance, stable transaminase levels, and good bile production during machine perfusion. The recipient experienced an uneventful postoperative course with immediate graft function and was discharged on postoperative day 8. Conclusions: Quasi ischemia‐free liver procurement represents a simpler alternative to ischemia‐free liver transplantation, potentially simplifying the implantation phase. This technique holds promise for improving outcomes in liver transplantation, particularly in cases involving marginal grafts.

  • Open Access

    Normothermic machine perfusion converges transplant induced transcript profiles in low and high risk DBD and DCD livers

    by Karen S. Keslar, Qiang Liu, William M. Baldwin, Brian T. Gaudette, Chase J. Wehrle, Keyue Sun, Chunbao Jiao, Mingyi Zhang, Khaled Ali, Beatrice Cazzaniga, et al.

    Normothermic machine perfusion (NMP) of donated livers is emerging as a superior preservation technology versus static cold storage (SCS) for transplant, transforming a metabolically dormant organ to a functioning state that improves outcomes of marginal liver transplants. Mechanisms underlying improved NMP restoration of donation after brain death (DBD) and donation after circulatory death (DCD) livers remain incompletely defined. We tested the hypothesis that NMP would decrease transcripts encoding inflammatory mediators following both perfusion and transplant of DBD and DCD livers. Biopsy transcript expression profiles were determined from SCS DBD livers at pre-SCS preservation and transplant reperfusion and from benchmark and outside benchmark criteria DBD and DCD livers pre-NMP, after 6–7 h of NMP, and after transplant reperfusion. Compared to SCS livers, NMP programs converged transcript profiles of DCD and DBD livers, decreasing transplant reperfusion-induced inflammatory transcripts while increasing transcripts promoting wound healing and tissue repair processes, but did not obviate the high occurrence of adverse events in the outside benchmark DCD livers transplants.


  • Open Access

    Machine perfusion of liver grafts: hypothermic versus normothermic versus normothermic regional perfusion

    by Damiano Patrono, Luca Del Prete, Janina Eden, Philipp Dutkowski, James V. Guarrera, Cristiano Quintini, Renato Romagnoli

    Machine perfusion (MP) techniques, including hypothermic oxygenated perfusion (HOPE), normothermic perfusion (NMP), and normothermic regional perfusion (NRP), have emerged as strategies to optimize outcomes of extended criteria donor (ECD) livers. Despite increasing adoption, clinical indications remain uncertain. To assist transplant professionals in clinical decision making, a systematic review and meta-analysis was conducted according to PRISMA guidelines, including randomized controlled trials (RCT) and cohort studies. Outcomes of interest were ischemic cholangiopathy (IC) and graft survival. Moderator analyses explored the influence of donor, recipient, and procedural factors. Studies comparing different MP techniques and sequential approached were also reviewed qualitatively. HOPE was associated with a significant reduction in IC (RR 0.50; CI 0.31, 0.79; P = 0.003) and improved graft survival (RR 1.08; CI 1.05, 1.08; P < 0.001), with evidence supported by RCT. NMP did not significantly influence IC or graft survival. Based on retrospective studies, NRP significantly improved IC (RR 0.1, CI 0.05, 0.21; P < 0.0001) and graft survival (RR 1.11; CI 1.05, 1.17; P = 0.0001) as compared to super-rapid recovery in controlled donation after circulatory death (DCD). Sequential approaches showed promise in high-risk grafts but require further validation. Studies comparing different MP approaches are still limited. Available literature is largely heterogeneous regarding risk profile and characteristic on included donors, study designs and considered endpoints, limiting the possibility to provide clear recommendation about clinical indications. Further comparative trials and studies focusing on specific donor-recipient scenarios are necessary to refine MP utilization and optimize LT outcomes.


  • Open Access

    The small-for-size syndrome in living donor liver transplantation: current management

    by Luca Del Prete, Cristiano Quintini, Teresa Diago Uso

    Small-for-size syndrome poses a significant challenge in living donor liver transplantation, with potentially severe consequences including liver failure and death. This review explores the management strategies for SFSS, starting from the pathophysiology of the disease. SFSS arises from insufficient liver mass in the graft and hyperdynamic circulation in cirrhotic recipients, leading to portal hyperperfusion and subsequent liver injury. Risk factors include graft size, quality, recipient factors, and hemodynamic changes during transplantation. Hemodynamic monitoring is crucial during living donor liver transplantation to optimize portal vein and hepatic artery flow. Prevention strategies focus on donor-recipient matching and intraoperative graft inflow modulation. Optimizing venous outflow and avoiding portal hyperperfusion is essential. Management of established small-for-size syndrome involves supportive care, pharmacologic interventions, and radiological and surgical options. Pharmacotherapy includes somatostatin analogues, beta-blockers, and vasopressin analogues to reduce portal flow and pressure. Surgical interventions aim to modulate portal flow and mitigate complications. Retransplantation may be necessary in severe cases, guided by persistent graft dysfunction despite liver flow modulations. In conclusion, preventing and managing small-for-size syndrome in living donor liver transplantation requires comprehensive assessment and tailored interventions. Advancements in graft/recipient matching, hemodynamic monitoring, pharmacologic and surgical techniques aiming to inflow modulation have improved outcomes, enabling successful transplantation even with ultra-small grafts.


  • Machine Perfusion or Straight to Transplant? Predictive Value of Flavin Mononucleotide Levels in Flush Solution of Human Liver Allograft

    by Khaled Ali, Beatrice Cazzaniga, Qiang Liu, Yuki Miyazaki, Munkhbold Tuul, Roma Raj, Ahmed Hussein, Chase Wehrle, Mingyi Zhang, Esteban Calderon, et al.

    Objective: This study examined the predictive value of flavin mononucleotide (FMN) levels in the flush solution used during cold storage of donor livers on outcomes post-transplantation. Background: Static cold storage for liver grafts induces hypoxia with subsequent impaired mitochondrial function and flavin mononucleotide (FMN) release upon reperfusion. Methods: This study enrolled 62 recipients who received whole liver grafts from donation after brain death (n=50) and circulatory death donors (n=12) between June 2022 and July 2023. FMN concentrations were measured in flush solutions on the back-table. The ROC-curve analysis identified an FMN level cutoff for graft survival. Post-transplant outcomes were examined according to FMN levels. Results: FMN level was significantly associated with graft survival, with an area under the curve of 0.858 (95% CI: 0.754–0.963, P P =0.686). The study cohort was divided into low-FMN (P =0.003). Levels of transaminases within 7 days post-transplant were significantly higher in the high-FMN group ( P =0.003). The high-FMN group developed acute rejections (41% vs 15%, P =0.023) and early allograft dysfunction (50% vs 20%, P =0.014) more frequently. The median comprehensive complication index in the high-FMN group was significantly higher [54 (interquartile range, 40–78) vs 42 (interquartile range, 28–52), P =0.017]. Conclusions: The FMN level measured in donor livers’ cold storage flush solution is a valid biomarker to predict post-transplant outcomes. Liver grafts with high FMN levels may benefit from machine perfusion to improve outcomes.


  • Open Access

    Correction: Obesity, organ failure, and transplantation: a review of the role of metabolic and bariatric surgery in transplant candidates and recipients

    by Omar M. Ghanem, Alejandro Pita, Mustafa Nazzal, Shaneeta Johnson, Tayyab Diwan, Nabeel R. Obeid, Kristopher P. Croome, Robert Lim, Cristiano Quintini, Bryan A. Whitson, et al.


  • Open Access

    Obesity, organ failure, and transplantation: a review of the role of metabolic and bariatric surgery in transplant candidates and recipients

    by Omar M. Ghanem, Alejandro Pita, Mustafa Nazzal, Shaneeta Johnson, Tayyab Diwan, Nabeel R. Obeid, Kristopher P. Croome, Robert Lim, Cristiano Quintini, Bryan A. Whitson, et al.

    Obesity is a risk factor for kidney, liver, heart, and pulmonary diseases, as well as failure. Solid organ transplantation remains the definitive treatment for the end-stage presentation of these diseases. Among many criteria for organ transplant, efficient management of obesity is required for patients to acquire transplant eligibility. End-stage organ failure and obesity are 2 complex pathologies that are often entwined. Metabolic and bariatric surgery before, during, or after organ transplant has been studied to determine the long-term effect of bariatric surgery on transplant outcomes. In this review, a multidisciplinary group of surgeons from the Society of American Gastrointestinal and Endoscopic Surgeons and the American Society for Transplant Surgery presents the current published literature on metabolic and bariatric surgery as a therapeutic option for patients with obesity awaiting solid organ transplantation. This manuscript details the most recent recommendations, pharmacologic considerations, and psychological considerations for this specific cohort of patients. Since level one evidence is not available on many of the topics covered by this review, expert opinion was implemented in several instances. Additional high-quality research in this area will allow for better recommendations and, therefore, treatment strategies for these complex patients.


  • Open Access

    Obesity, organ failure, and transplantation: A review of the role of metabolic and bariatric surgery in transplant candidates and recipients

    by Omar M. Ghanem, Alejandro Pita, Mustafa Nazzal, Shaneeta Johnson, Tayyab Diwan, Nabeel R. Obeid, Kristopher P. Croome, Robert Lim, Cristiano Quintini, Bryan A. Whitson, et al.


  • Expanding Selection Criteria in Deceased Donor Liver Transplantation for Hepatocellular Carcinoma: Long-term Follow-up of a National Registry and 2 Transplant Centers

    by Chase J. Wehrle, Jiro Kusakabe, Miho Akabane, Marianna Maspero, Bobby Do Zervos, Jamak Modaresi Esfeh, Maureen Whitsett Linganna, Yuki Imaoka, Mazhar Khalil, Alejandro Pita, et al.

    Background.: This study compares selection criteria for liver transplant (LT) for hepatocellular carcinoma (HCC) for inclusivity and predictive ability to identify the most permissive criteria that maintain patient outcomes. Methods.: The Scientific Registry of Transplant Recipients (SRTR) database was queried for deceased donor LT’s for HCC (2003–2020) with 3-y follow-up; these data were compared with a 2-center experience. Milan, University of California, San Francisco (UCSF), 5-5-500, Up-to-seven (U7), HALT-HCC, and Metroticket 2.0 scores were calculated. Results.: Nationally, 26 409 patients were included, and 547 at the 2 institutions. Median SRTR-follow-up was 6.8 y (interquartile range 3.9–10.1). Three criteria allowed the expansion of candidacy versus Milan: UCSF (7.7%, n = 1898), Metroticket 2.0 (4.2%, n = 1037), and U7 (3.5%, n = 828). The absolute difference in 3-y overall survival (OS) between scores was 1.5%. HALT-HCC (area under the curve [AUC] = 0.559, 0.551–0.567) best predicted 3-y OS although AUC was notably similar between criteria (0.506 < AUC < 0.527, Mila n = 0.513, UCSF = 0.506, 5-5-500 = 0.522, U7 = 0.511, HALT-HCC = 0.559, and Metroticket 2.0 = 0.520), as was Harrall’s c-statistic (0.507 < c-statistic < 0.532). All scores predicted survival to P < 0.001 on competing risk analysis. Median follow-up in our enterprise was 9.8 y (interquartile range 7.1–13.3). U7 (13.0%, n = 58), UCSF (11.1%, n = 50), HALT-HCC (6.4%, n = 29), and Metroticket 2.0 (6.3%, n = 28) allowed candidate expansion. HALT-HCC (AUC = 0.768, 0.713–0.823) and Metroticket 2.0 (AUC = 0.739, 0.677–0.801) were the most predictive of recurrence. All scores predicted recurrence and survival to P < 0.001 using competing risk analysis. Conclusions.: Less restrictive criteria such as Metroticket 2.0, UCSF, or U7 allow broader application of transplants for HCC without sacrificing outcomes. Thus, the criteria for Model for End-stage Liver Disease-exception points for HCC should be expanded to allow more patients to receive life-saving transplantation.


  • Open Access

    Uterus transplantation: a rescue technique to save the viability and functionality of the graft after intra-operative outflow thrombosis

    by Giuseppe D'AMico, Koji Hashimoto, Luca Del Prete, Elliott Richards, Stephanie Ricci, Rebecca Flyck, Bijan Eghtesad, Teresa Diago, Tommaso Falcone, Charles Miller, et al.